Revenue Update on Neuralstem(NYSEMKT:CUR)

Neuralstem(NYSEMKT:CUR) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.58. The reported EPS was below estimates by -11.54%. Analysts had estimated an EPS of $-0.52.

Neuralstem (CUR) made into the market gainers list on Fridays trading session with the shares advancing 0.92% or 0.05 points. Due to strong positive momentum, the stock ended at $5.5, which is also near the day’s high of $5.55. The stock began the session at $5.46 and the volume stood at 82,319 shares. The 52-week high of the shares is $10.66001 and the 52 week low is $2.470002. The company has a current market capitalization of $61 M and it has 1,10,45,480 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Feb 27, 2017, Richard J Daly (CEO) purchased 2,591 shares at $3.86 per share price.Also, On Sep 26, 2016, Jones Jonathan Brian Lloyd (CFO) purchased 31,250 shares at $0.32 per share price.On Nov 16, 2015, Karl Johe (Chief Scientific Officer) sold 25,000 shares at $1.09 per share price, according to the Form-4 filing with the securities and exchange commission.

Neuralstem Inc. (Neuralstem) is engaged in development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and its small molecule compounds. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from all areas of the developing human brain and spinal cord thus enabling the generation of physiologically relevant human neurons of all types. It has developed and patented a series of small molecule compounds. The Company is developing products using technology including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company has a wholly owned subsidiary Suzhou Sun-Now Biopharmaceutical Co. Ltd. in China. Its clinical programs include the NSI-566 and NSI-189.

Add Comment